KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day
or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose
combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus
levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and
tolerability of these compounds over the 48 week study period in patients naive to anti-HIV
therapy.